| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 24, 2007
Accepted on August 8, 2007
From the Department of Cardiovascular Medicine (A.D., C.H., L.S., J.L.M.), University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Ark; the Department of Pharmacology (C.H.), School of Pharmaceutical Sciences, Central South University, Changsha, China; and the Department of Ophthalmology (L.S.), Heping Hospital, Changzhi Medical College, Changzhi, China.
* To whom correspondence should be addressed. E-mail: MehtaJL{at}uams.edu.
Objective—Vascular endothelial growth factor (VEGF), a key angiogenic growth factor, stimulates angiogenesis. Low levels of reactive oxygen species (ROS) function as signaling molecules for angiogenesis. We postulated that low concentrations of oxLDL might induce low levels of ROS and initiate angiogenesis.
Methods and Results—An in vitro model of tube formation from human coronary artery endothelial cells (HCAECs) was used. oxLDL (0.1, 1, 2, 5 µg/mL) induced VEGF expression and enhanced tube formation. oxLDL-mediated VEGF expression and tube formation were suppressed by a specific blocking anti–LOX-1 antibody. Anti–LOX-1 antibody also reduced oxLDL-induced increase in the expression of NADPH oxidase (gp91phox and p47phox subunits) and subsequent intracellular ROS generation, phosphorylation of p38 as well as p44/42MAPK, and NF-
B p65 expression. gp91phox siRNA had a similar effect. The expression of VEGF and NF-
B p65 induced by oxLDL was also inhibited by the specific extracellular signal-regulated kinase (ERK) 1/2 inhibitor U0126 and the p38 MAPK inhibitor SB203580. Importantly, the NADPH oxidase inhibitor apocynin, gp91phox siRNA, U0126, and SB203580 all reduced tube formation in response to oxLDL.
Conclusions—These findings suggest that small concentrations of oxLDL promote capillary tube formation by inducing the expression of VEGF via LOX-1-mediated activation of NADPH oxidase- MAPKs-NF-
B pathway.
This article has been cited by other articles:
![]() |
A. M. Vincent, J. M. Hayes, L. L. McLean, A. Vivekanandan-Giri, S. Pennathur, and E. L. Feldman Dyslipidemia-Induced Neuropathy in Mice: The Role of oxLDL/LOX-1 Diabetes, October 1, 2009; 58(10): 2376 - 2385. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tian, S. Jain, S. E. Kelemen, and M. V. Autieri AIF-1 expression regulates endothelial cell activation, signal transduction, and vasculogenesis Am J Physiol Cell Physiol, February 1, 2009; 296(2): C256 - C266. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hu, A. Dandapat, L. Sun, J. A. Khan, Y. Liu, P. L. Hermonat, and J. L. Mehta Regulation of TGF{beta}1-mediated Collagen Formation by LOX-1: Studies Based on Forced Overexpression of TGF{beta}1 in Wild-Type and Lox-1 J. Biol. Chem., April 18, 2008; 283(16): 10226 - 10231. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |